Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoîne Italiano, Vincent Ribrag, Carlo Lucchesi et al.|The Lancet Oncology|2018Cited by 614
Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapyMarieke A. de Graaff, Judith V.M.G. Bovée, Marije A. J. de Rooij et al.|British Journal of Cancer|2016Cited by 19